Navigation Links
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Date:9/4/2007

tation, and 3 were EGFR wild-type.

-- All 6 patients with EGFR-activating mutations demonstrated clinical

benefit (5 PR, 1 SD).

-- XL647 is generally well tolerated in this patient population. The most

frequently reported adverse events assessed as being related to XL647

were diarrhea, rash, fatigue, and nausea, all of which were Grade 1 or

Grade 2 in severity.

"The data reported today demonstrate that XL647 has potential utility in patient populations with both mutated and wild-type EGFR," said Dr. Shirish Gadgeel of Karmanos Cancer Institute at Wayne State University. "Importantly, the data highlight that patients to date appear to have milder EGFR-related side-effects -- rash and diarrhea -- than previously described with other EGFR inhibitors while retaining potent anti-tumor activity with durable responses and stable disease. Although these are early results, they provide a compelling rationale for expediting the full development of XL647 in non-small cell lung cancer."

"These data suggest that XL647 has the potential for utility in patients with NSCLC who have an activating EGFR mutation and those with wild-type EGFRs. We believe these data support an aggressive clinical development strategy in first, second and third-line treatment as both a single agent and in combination with other therapies," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "Moreover, new data from an ongoing phase 1 trial of XL647 suggest that daily dosing results in higher drug concentrations than those observed to date in this phase 2 study with intermittent dosing. We expect to complete this evaluation of both daily and intermittent dosing schedules soon in order to select the optimal regimen and dose for the late-stage development of XL647."

The most frequently reported treatment-related adverse events (AEs) were Grade 1 and 2 diarrhea and fatigue, and Grade 1 nausea and rash. Six pat
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... SAN DIEGO , July 28, 2014 ... algae cultivation technologies, today announced the appointment of biotechnology ... member of the board of directors. Levine replaces Cynthia ... effective immediately. She will remain chairman of the company,s ... leadership on Sapphire Energy,s mission to deliver commercial scale ...
(Date:7/28/2014)... Reston, VA (PRWEB) July 28, 2014 ... leading nonprofit authority on the use of health IT ... its Health Plan Identifier (HPID) Workgroup has ... Between a Health Plan and Payer?” The HPID Workgroup, ... worked closely with the Centers for Medicare and Medicaid ...
(Date:7/28/2014)... Texas (PRWEB) July 28, 2014 ... and China Lubricant Industry” is a professional ... Global Lubricant market. The report introduces Lubricant ... and industry chain structure and industry overview. ... including China’s domestic market as well as ...
(Date:7/28/2014)... 2014 According to a new ... "Regenerative Medicine (Bone and Joint) Market (By Technology ... By Applications - Bone Graft Substitutes, Osteoarticular Diseases, ... Industry Analysis, Size, Share, Growth, Trends and Forecast, ... and joint) market was valued at USD 2.6 ...
Breaking Biology Technology:Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Regenerative Medicine Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4
... for faster and better business analysis, reporting and decision-making , ... ... ( www.visual-io.com ) today announced and unveiled the newest generation ... intelligence at the IBM Cognos Forum ( http://www.cognos.com/cognosforum/ ), taking place ...
... Partnering Strategy and Process for Picoplatin -SOUTH SAN FRANCISCO, ... PARD ), a biopharmaceutical company focused on innovative ... chief operating officer, will present at the BIO International ... Time in Atlanta. Mr. Martell will provide an ...
... 12 Masimo Corporation (Nasdaq: MASI ), the ... oximetry, today announced that its management is scheduled to present ... Boston, Massachusetts, on Tuesday, May 19, 2009, at 2:35 p.m. ... available on the Masimo website at www.masimo.com . ...
Cached Biology Technology:Visual i/o Combines Advanced Dynamic Visual Business Intelligence and Search Through New Software 2Visual i/o Combines Advanced Dynamic Visual Business Intelligence and Search Through New Software 3Visual i/o Combines Advanced Dynamic Visual Business Intelligence and Search Through New Software 4Poniard Pharmaceuticals to Present at the 2009 BIO International Convention 2Poniard Pharmaceuticals to Present at the 2009 BIO International Convention 3Masimo to Present at the Deutsche Bank 34th Annual Health Care Conference 2
(Date:7/27/2014)... A new in vitro study has revealed that nicotine ... DNA damage caused by a certain carcinogen in smoke. ... the curing of tobacco leaves and ultimately ends up ... in the lung and liver, where it is activated ... Previous research in mice has revealed that nicotine can ...
(Date:7/27/2014)... -- Microorganisms like bacteria and fungi can evade treatment ... or antifungal drugs. These permanent mutations were once thought ... evolve. Now a new study has shown that microorganisms ... known as epimutations -- to gain the benefits of ... mechanism was discovered in a fungus called Mucor circinelloides, ...
(Date:7/27/2014)... scientists have identified more than two dozen genetic ... that had not been previously reported. The study, ... funded by the National Institutes of Health (NIH) ... , "Unraveling the genetic underpinnings of Parkinson,s is ... this complex disease, and hopefully, may one day ...
Breaking Biology News(10 mins):Nicotine found to inhibit DNA-strand break caused by a certain carcinogen in smoke 2Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3NIH scientists find 6 new genetic risk factors for Parkinson's 2
... researchers at the University of Illinois published a discovery that ... discovery which was based on an analysis of ribosomal ... cells opened up a new field of study, and ... To mark the anniversary of this discovery, the university ...
... Research Charity --Presents 2007 Prizes ,for Outstanding Psychiatric Research ... Prize winners have significantly contributed to the knowledge ... disorders NEW YORK, N.Y., Oct. 16, 2007Five of ... presented to scientists of great achievement by NARSAD, the ...
... after an American was hanged in London in one of ... forensic science at Michigan State University is producing evidence that ... hanged for murdering and dismembering his showgirl wife, then fleeing ... in hot pursuit. Loaded with enough sordid details and twists ...
Cached Biology News:Symposium marks 30th anniversary of discovery of third domain of life 2Symposium marks 30th anniversary of discovery of third domain of life 3Symposium marks 30th anniversary of discovery of third domain of life 4NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 2NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 3NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 4NARSAD presents 2007 prizes for outstanding achievement in neuroscience and psychiatric research 5Science casts doubt on famous British murder case 2Science casts doubt on famous British murder case 3
Monkey IL-2 ELISPOT Kit with white/opague microtiter plates...
B2-Microgloulin...
...
... EVO series offers versatile liquid handling platforms ... a wide variety of life science applications.The ... base sizes (75, 100, 150 and 200 ... a platform that will advance with their ...
Biology Products: